Lei Ding

Lei Ding is the Associate Director of Discovery at IN8bio, leading research on CAR gamma delta T immunotherapy and CRISPR/Cas genome editing. Lei was previously a Scientist I at The University of Alabama at Birmingham, where they optimized gene correction for sickle cell mutations and engineered modified Cas9 proteins. As a Postdoctoral Researcher, Lei developed a novel CRISPR/Cas9 technology that enhanced cell viability and successfully cured a humanized sickle cell disease mouse model. Lei earned a Ph.D. in Biochemistry and Molecular Genetics from the same institution, where their doctoral research focused on nucleic acid binding proteins.